Pharmaceutical and med device giant Abbott (NYSE: ABT) said today that it had received approval from the Food and Drug Administration (FDA) for its next-generation integrated continuous glucose ...
ACTON, Mass.--(BUSINESS WIRE)-- Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced ...
The FDA has approved the FreeStyle® Libre 2 integrated continuous glucose monitoring system (Abbott) for adults and children ≥4 years of age with diabetes. The Food and Drug Administration (FDA) has ...
- TRICARE members now have faster, easier, and more convenient access to continuous glucose monitoring - Abbott’s FreeStyle Libre 2 system will now be on the brand-name formulary and available through ...
Abbott’s continuous glucose monitoring system, the FreeStyle Libre 2, has been approved in Canada for adults and children four years and older with diabetes. The FreeStyle Libre 2 system continuously ...
ABBOTT PARK, Ill., June 22, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that the French health authority has approved the expansion of reimbursement coverage for its FreeStyle Libre 2 ...
The FreeStyle Libre 3 glucose monitoring system (Abbott) has been granted a CE mark for use by people with diabetes in the countries of the European Union (EU). The next-generation FreeStyle Libre 3 ...
"The best healthcare solution is the one that helps the most people, which is why we designed our FreeStyle Libre portfolio with access and affordability in mind from the very beginning," said ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback